Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01938248
Recruitment Status : Recruiting
First Posted : September 10, 2013
Last Update Posted : May 30, 2017
Bristol-Myers Squibb
Canadian Institutes of Health Research (CIHR)
Hamilton Health Sciences Research Institute
Hamilton Health Sciences Foundation
Information provided by (Responsible Party):
Jeff Healey, Population Health Research Institute

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2020
  Estimated Study Completion Date : April 2021